Ioflupano (123i) Rotop

Ioflupane, the active ingredient in Ioflupano (123i) Rotop, is a radiopharmaceutical presented as an injectable solution for intravenous use. It enables visualization of dopamine transporters to aid the diagnosis of Parkinsonian syndromes and other movement disorders in adult patients. GNH USA supplies Ioflupano (123i) Rotop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Ioflupane is used in nuclear medicine to image dopaminergic pathways and assist in the evaluation of movement‑related conditions. - Differential diagnosis of Parkinsonian syndromes: visualizes dopamine transporter loss to distinguish Parkinson's disease from other parkinsonian disorders. - Evaluation of movement disorders: provides quantitative SPECT data on nigrostriatal integrity for clinical decision‑making. - Assessment of dopaminergic neuron integrity: helps monitor disease progression and therapeutic response in research and specialized care settings.

Adverse reactions may occur following administration of Ioflupane.

Common Side Effects: - Headache: mild to moderate intensity, transient. - Nausea: occasional, usually resolves without intervention. - Injection site pain or erythema: localized discomfort at the IV site. - Dizziness or light‑headedness: may occur shortly after dosing. - Mild hypotension: transient blood pressure drop. - Fatigue: temporary feeling of tiredness.

Serious or Rare Side Effects: - Allergic reaction: rash, pruritus, or urticaria. - Anaphylaxis: severe, potentially life‑threatening hypersensitivity. - Severe hypotension: marked drop in blood pressure requiring medical attention. - Seizure: rare neurologic event. - Pulmonary edema: uncommon respiratory compromise. - Severe rash or Stevens‑Johnson‑like reaction: requires immediate discontinuation.

When using Ioflupane, clinicians should consider several safety measures. - Pregnancy: safety not established; avoid unless the diagnostic benefit outweighs potential risk. - Breastfeeding: unknown excretion; consider discontinuing nursing or using alternative imaging. - Renal impairment: assess renal function; altered clearance may affect image quality. - Concomitant dopamine‑active drugs: evaluate for potential competition at the transporter site. - Radiation exposure: limit repeat scans and ensure appropriate shielding for staff. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Ioflupane may interact with substances that affect dopamine transporter binding or radiopharmaceutical distribution.

Major Interactions (Avoid): - Cocaine or amphetamine use: competitive inhibition of dopamine transporter binding may reduce tracer uptake. - Other dopamine‑transporter radioligands: simultaneous administration can interfere with image interpretation.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may modestly alter striatal binding patterns. - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): may affect tracer distribution. - Typical or atypical antipsychotics: can decrease dopamine transporter availability, influencing imaging results.